This is a working overview of fatty diacid, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-08. Anything still debated is marked as such rather than presented as settled.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
=== Short-term training programmes === These are conducted at RCB by inducting post-graduate students of science from various universities/institutions/colleges to carry out their project/ dissertation work towards partial fulfillment of their postgraduate degrees.
While electronic review later indicated the serve was out, Roland Garros does not use Hawk-Eye as an official officiating tool; instead, the technology is used exclusively for television broadcasts. It is noted that the broadcast version of Hawk-Eye operates with significantly lower precision than the official Electronic Line Calling (ELC) systems installed at other tournaments, leaving open the possibility that the umpire's ruling on the clay mark was accurate. However, the overrule generated controversy. Had the call not been overturned, Zverev would have broken back. Tennis commentator Robbie Koenig and former world No. 1 Andy Roddick disagreed with the overrule. Zverev would go on to lose the fifth set, giving up his two-sets-to-one lead and finishing runner-up to Carlos Alcaraz, who collected his maiden French Open title. In Halle, Zverev reached the semifinals after collecting wins against Oscar Otte, Lorenzo Sonego, and Arthur Fils, losing to Hubert Hurkacz in straight sets. At Wimbledon, Zverev beat Roberto Carballés Baena, Marcos Giron, and Cameron Norrie before losing to Taylor Fritz in the fourth round. His third-set tiebreak with Norrie was noted as one of the longest tiebreaks of the tournament, with Zverev prevailing 17–15 after 26 minutes. Back on clay, Zverev reached the final in Hamburg, losing to Arthur Fils in three sets. At the Olympic Games in Paris, Zverev represented Team Germany as defending champion.
The strong inheritance pattern prompted several researchers, including Smith Ely Jelliffe, to attempt to trace and connect family members of previous studies. Jelliffe collected information from across New York and published several articles regarding the genealogy of HD in New England. Jelliffe's research roused the interest of his college friend, Charles Davenport, who commissioned Elizabeth Muncey to produce the first field study on the East Coast of the United States of families with HD and to construct their pedigrees. Davenport used this information to document the variable age of onset and range of symptoms of HD; he claimed that most cases of HD in the US could be traced back to a handful of individuals. This research was further embellished in 1932 by P. R. Vessie, who popularized the idea that three brothers who left England in 1630 bound for Boston were the progenitors of HD in the US. The claim that the earliest progenitors had been established and eugenic bias of Muncey's, Davenport's, and Vessie's work contributed to misunderstandings and prejudice about HD. Muncey and Davenport also popularized the idea that in the past, some with HD may have been thought to be possessed by spirits or victims of witchcraft, and were sometimes shunned or exiled by society. This idea has not been proven through scientific research. Researchers have found contrary evidence; for instance, the community of the family studied by George Huntington openly accommodated those who exhibited symptoms of HD.
Sources: en.wikipedia.org
== Early years == Mariusz Pudzianowski was born in Biała Rawska, Poland. His father, Wojciech, was a weightlifter. Pudzianowski quickly became interested in sports. Since the age of 11, he has been training the Kyokushin style of karate. His current grade is 4th kyu green belt. He began strength training at the age of thirteen. When he was fifteen, Pudzianowski also started training boxing, quitting after seven years. Pudzianowski debuted in professional sports at the age of sixteen, taking part in Polish Weightlifting Championship, in the bench press event.
Until the 1960s various manufacturers offered alleged wrinkle creams for external use (Hormocenta of Hormocenta Cosmetic Böttger GmbH, or Placentubex C of Merz Pharmaceuticals) containing human fat from placentas collected from midwives and obstetric departments for industrial purposes. The use of human placentas was terminated in favour of animal products. In 2009, a group of Peruvian gangsters, nicknamed "pishtacos" by the police, was accused of having manufactured and marketed human fat. However, the Peruvian Ministry of the Interior later described these allegations as a hoax. In the 2010s, MTF Biologics started providing Renuva (human cadaver fat) in syringes of up to 3 cubic centimetres (0.18 cu in). In 2024, Tiger Aesthetics marketed alloClae in syringes of up to 22 cubic centimetres (1.3 cu in). These preparations are being used as cosmetic filler. The demand has risen since the popularization of GLP-1 drugs has left thinner patients that feel that they lost fat in places that do not look good. Doctors say that customers are not concerned by the origin of the fat. Donors may have not been clear about the commercial use of their remains. In 2024, the New York State Health Department have denied a license to alloClae over doubts about the compliance with tissue donation laws. There can be complications with cadaver fat injections. If the fat does not vascularize, it may necrose, as in fat grafting from the patient's own body, but there are no studies comparing both methods. Cultural critic Arabelle Sicardi have compared alloClae to 2024 film The Substance.
16 January – Analysis shows that Labour would need a record swing of 12.7% in votes at the next general election to win a majority in the House of Commons. Lee Anderson and Brendan Clarke-Smith resign their positions as Deputy Chairmen of the Conservative Party, after saying they would back rebel amendments on the Rwanda bill. Jane Stevenson also resigns as a Parliamentary Private Secretary so she can vote for the amendment. The fifteen-year time limit on voting eligibility for British citizens living abroad is abolished under the Elections Act 2022, enabling a further two million people to register to vote in UK elections. 17 January – The UK government is seeking legal expenses from the Scottish Government over its challenge against the veto of the Gender Recognition Reform (Scotland) Bill. The current session of the 7th Northern Ireland Assembly is suspended following the failure of Democratic Unionist Party to support nominations to elect Mike Nesbitt (UUP) or Patsy McGlone (SDLP) to the role of Speaker of the Northern Ireland Assembly. The Safety of Rwanda (Asylum and Immigration) Bill passes its third reading in the House of Commons with MPs voting 320–276 in favour of the bill. 18 January – The UK Statistics Authority rebuked the prime minister for misleading the public over the backlog of asylum applications, which he said in a social media post had been cleared, while several thousand still remained. The UKSA said the allegation could have affected public trust in the government.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.